$DYAI — Small-cap biotech I think is worth putting on the radar: commercial proteins + C1 platform + Gates/Scripps collaborations

I've been digging into **Dyadic International (NASDAQ: DYAI)** and think it deserves a closer look from anyone researching small-cap biotech, micro-caps and emerging biomanufacturing companies. **This isn't a "DYAI is going to 10x tomorrow" post.** The interesting part to me is the underlying business transition and the number of different ways the technology could potentially create value. Here's what caught my attention: # 1. It's not a traditional binary biotech Dyadic isn't betting the company on getting **one drug** through clinical trials. The company has developed proprietary microbial protein-production platforms — primarily **C1 and Dapibus™** — that are being applied across life sciences, food & nutrition and bio-industrial markets. That potentially creates several different revenue paths: * Product sales * Licensing * Milestone payments * Partner revenue * Potential profit sharing * Co-development That's a fundamentally different risk/reward profile from a micro-cap biotech with a single therapeutic candidate. # 2. They're actually moving toward commercialization This is probably the part I find most interesting. Dyadic reported **$1.11 million in Q1 2026 revenue, up 182.3% YoY**. The company also reported commercial launches involving recombinant human albumin and recombinant DNase I, initial purchase orders for recombinant bovine transferrin, and an OEM distribution agreement with IBT Bioservices. The company has also been expanding its commercial relationships with companies such as **Proliant, Fermbox Bio, IBT Bioservices and BRIG Bio**. The bigger question for me isn't whether DYAI can announce partnerships. It's:

That's the metric I'd be watching. # 3. The C1 platform is getting some interesting validation This is where the story gets more speculative—but potentially much more interesting. Dyadic has been working with organizations including **Scripps Research, the Gates Foundation and Fondazione Biotecnopolo di Siena** on protein/antibody development programs. In July, Dyadic said it developed stable C1 cell lines and initially purified two Scripps-designed Bundibugyo Ebola recombinant protein antigens in approximately **15 days** after receiving the plasmids. The company has also highlighted C1 programs involving RSV, malaria and H5 avian influenza, including Gates Foundation-supported work. Obviously, collaboration ≠ commercialization, and none of this means DYAI is going to develop a successful drug. But the platform validation is interesting. # 4. There's another side of the story that I think the market could overlook The company isn't only pursuing biopharma. Dyadic has been expanding into: **Life Sciences → Food & Nutrition → Bio-industrial** The latest bio-industrial initiative involves a proprietary industrial enzyme program focused on advanced cellulose processing and builds on the company's EN3ZYME™ commercialization. That diversification is important because it gives the company multiple potential commercial applications for the underlying protein-production technology. # 🇯🇵 5. They're also building international IP/commercial infrastructure In June, Dyadic announced that the Japan Patent Office had allowed claims covering aspects of its proprietary recombinant protein expression technology. The company described the development as part of its broader Japan market expansion and business-development strategy. Again, an IP allowance isn't revenue—but it's another piece of the platform story. # So what's the actual investment thesis? For me, the interesting thesis isn't: **"DYAI is a cheap biotech."** It's:

If that happens, the valuation framework could look very different from that of a traditional early-stage biotech. The company itself says its strategy is increasingly focused on product commercialization, distribution, partnerships and recurring revenue opportunities. And importantly, on July 24 Dyadic announced that Nasdaq had confirmed it had **regained compliance with the applicable listing requirements**, so the immediate Nasdaq listing issue was resolved. # But here's what I'd be watching on the bear side There are definitely reasons **not** to blindly jump into this. DYAI remains a small, loss-making company. Q1 2026 net loss was approximately **$1.95 million**, and cash, cash equivalents, restricted cash and investment securities were approximately **$6.6 million** at March 31. I'd specifically be watching: **1. Revenue quality** How much revenue becomes recurring product revenue versus grants, milestones and development revenue? **2. Cash burn** Can commercialization grow faster than expenses? **3. Dilution/capital requirements** Small biotech companies need capital, so shareholder dilution is always something to monitor. **4. Commercial adoption** Are customers actually ordering meaningful quantities of Dyadic products? **5. Platform monetization** Can C1/Dapibus translate into licensing, royalties, product sales or other economically meaningful agreements? **6. Execution** There are a lot of programs. The company needs to demonstrate that it can turn this pipeline into commercial results. # My takeaway I don't think **DYAI is a risk-free story**—far from it. But I do think it's an interesting one to research because you're potentially looking at **a protein-manufacturing platform rather than a single-drug biotech**. You've got: 🧬 Proprietary C1 + Dapibus platforms 💰 Commercial products and distribution relationships 📈 Q1 revenue growth 🤝 Multiple strategic collaborations 🌎 Life sciences + food/nutrition + bio-industrial applications 🧪 Scripps/Gates/FBS-related programs 🇯🇵 Expanding international IP/commercial activity 📊 A very small market-cap profile The next stage of the story, IMO, is **proving that all of this activity converts into sustainable revenue growth and eventually better economics.** That's what would make me significantly more interested. **Curious what others think:** Is DYAI better viewed as a traditional speculative biotech, or as a potentially undervalued **biomanufacturing/platform company**? **Disclosure:** This is not financial advice. I have no idea where the stock goes from here. Do your own due diligence, read the company's SEC filings, and understand the risks before buying anything.